 |
  
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
U.S. News Achillion's Hepatitis C Drug Gets FDA Fast TrackJanuary 5, 2012 New Haven, Conn.-based Achillion Pharmaceuticals announced that the Food and Drug Administration has granted fast-track designation to its experimental treatment for hepatitis C virus. The drug, ACH-1625, is currently in a mid-stage trial. Fast-track status expedites FDA's review of drugs intended to treat serious illnesses and fill unmet medical needs. Reuters 01.04.2012  This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before adding your comment, please read TheBody.com's Comment Policy.) |
 |
Email
Comments
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
